Related Experiment Videos
Diagnosing and treating small-cell carcinomas of prostatic origin
Michael E Spieth1, Y Gregory Lin, Thanhcuong T Nguyen
1Department of Radiology, Marshfield Clinic, Wisconsin 54449, USA. spiethm@mfldclin.edu
Clinical Nuclear Medicine
|January 24, 2002
Summary
Treatment with somatostatin analogs shows promise for aggressive prostate cancer. This approach, using octreotide acetate, led to significant pain relief and tumor shrinkage in a patient with metastatic small-cell carcinoma.
Area of Science:
- Oncology
- Nuclear Medicine
- Endocrinology
Background:
- Small-cell carcinoma is an aggressive prostate cancer subtype often resistant to chemotherapy.
- Combined tumors of small-cell carcinoma and adenocarcinoma are common in prostate cancer.
- Androgen-independent prostate cancer lacks effective treatment options.
Observation:
- A patient with metastatic prostate cancer, exhibiting neuroendocrine differentiation, was treated with octreotide acetate.
- In-111 OctreoScan scintigraphy demonstrated superior sensitivity for detecting metastatic foci compared to bone scanning.
- The patient received treatment with a cold somatostatin derivative.
Findings:
- Therapy with the somatostatin derivative resulted in rapid pain relief and significant tumor shrinkage.
- The patient achieved a remission lasting at least 10 weeks.
- In-111 OctreoScan proved more sensitive than bone scanning for metastatic disease detection.
Implications:
- Somatostatin analogs are recommended as adjuvant treatments for high-risk prostate carcinoma patients.
- These analogs may be beneficial for detecting and treating small-cell carcinomas in both prostate and lung.
- Further research into somatostatin derivatives for advanced prostate cancer is warranted.